Results 21 to 30 of about 191,709 (318)

Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line [PDF]

Genetics and Molecular Biology, 2023
Genetically antimicrobial resistance in Mycobacterium tuberculosis is currently one of the most important aspects of tuberculosis, considering that there are emerging resistant strains for almost every known drug used for its treatment.
Nicolas de Oliveira Rossini, Marcio Vinicius Bertacine Dias   +1 more
doaj   +1 more source

Surface charge modulation of rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus biofilms

Journal of Nanobiotechnology, 2021
Background After the golden age of antibiotic discovery, bacterial infections still represent a major challenge for public health worldwide. The biofilm mode of growth is mostly responsible for chronic infections that current therapeutics fail to cure ...
D. da Costa, C. exbrayat-heritier, B. Rambaud, S. Megy, R. Terreux, B. Verrier, C. Primard   +6 more
semanticscholar   +1 more source

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy [PDF]

, 2016
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after ...
Anthony, Richard, Bratschi, Martin W., Cambau, Emmanuelle, Cavaliero, Arielle, Kasang, Christa, Mieras, Liesbeth, Perera, Geethal, Reichman, Lee, Richardus, Jan Hendrik, Saunderson, Paul, Steinmann, Peter, van Brakel, Wim, van den Broek, Jacques, Yew, Wing Wai   +13 more
core   +10 more sources

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin

European Respiratory Journal, 2021
Background Accumulating data indicate that higher rifampicin doses are more effective and shorten tuberculosis (TB) treatment duration. This study evaluated the safety, tolerability, pharmacokinetics, and 7- and 14-day early bactericidal activity (EBA ...
L. T. Te Brake, Veronique R. de Jager, K. Narunsky, N. Vanker, E. Svensson, P. Phillips, S. Gillespie, N. Heinrich, M. Hoelscher, R. Dawson, A. Diacon, R. Aarnoutse, M. Boeree   +12 more
semanticscholar   +1 more source

Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda

The Lancet Microbe, 2020
Summary: Background: The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert. Methods: We
Jean Claude Semuto Ngabonziza, MSc, Tom Decroo, PhD, Patrick Migambi, MSc, Yves Mucyo Habimana, MD, Armand Van Deun, PhD, Conor J Meehan, PhD, Gabriela Torrea, PhD, Faridath Massou, PharmD, Willem Bram de Rijk, BS, Bertin Ushizimpumu, BS, Esdras Belamo Niyigena, BS, Emil Ivan, PhD, Jules Mugabo Semahore, MD, Jean Baptiste Mazarati, PhD, Corinne Simone Merle, PhD, Philip Supply, PhD, Dissou Affolabi, ProfPhD, Leen Rigouts, PhD, Bouke Catherine de Jong, ProfPhD   +18 more
doaj   +1 more source

Biodegradable and Bioactive Carriers Based on Poly(betulin disuccinate-co-sebacic Acid) for Rifampicin Delivery

Pharmaceutics, 2022
This paper describes the preparation and characterization of polymer-drug systems based on polymeric microspheres obtained from poly(betulin disuccinate-co-sebacic acid).
Daria Niewolik, Barbara Bednarczyk-Cwynar, Piotr Ruszkowski, Alicja Kazek-Kęsik, Grzegorz Dzido, Katarzyna Jaszcz   +5 more
doaj   +1 more source

The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus

Antibiotics, 2022
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S.
Jan Balansky, Kenneth Pfarr, Christiane Szekat, Stefan Kehraus, Tilman Aden, Miriam Grosse, Rolf Jansen, Thomas Hesterkamp, Andrea Schiefer, Gabriele M. König, Marc Stadler, Achim Hoerauf, Gabriele Bierbaum   +12 more
doaj   +1 more source

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial.

Journal of Antimicrobial Chemotherapy, 2021
BACKGROUND Rifampicin doses of 40 mg/kg in adults are safe and well tolerated, may shorten anti-TB treatment and improve outcomes, but have not been evaluated in children.
A. Garcia-Prats, E. Svensson, J. Winckler, H. Draper, L. Fairlie, L. E. van der Laan, Masebole Masenya, H. S. Schaaf, L. Wiesner, J. Norman, R. Aarnoutse, M. Karlsson, P. Denti, A. Hesseling   +13 more
semanticscholar   +1 more source

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

Clinical pharmacology and therapy, 2020
To address the most appropriate endogenous biomarker for drug–drug interaction risk assessment, eight healthy subjects received an organic anion transporting polypeptide 1B (OATP1B) inhibitor (rifampicin, 150, 300, and 600 mg), and a probe drug cocktail (
Daiki Mori, Emi Kimoto, Brian Rago, Yusuke Kondo, Amanda J. King-Ahmad, R. Ramanathan, L. Wood, Jillian G. Johnson, V. Le, M. Vourvahis, A. David Rodrigues, C. Muto, K. Furihata, Y. Sugiyama, H. Kusuhara   +14 more
semanticscholar   +1 more source

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis

Archives of Disease in Childhood, 2021
Objective To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM).
R. Ruslami, F. Gafar, V. Yunivita, I. Parwati, A. Ganiem, R. Aarnoutse, B. Wilffert, J. C. Alffenaar, H. Nataprawira   +8 more
semanticscholar   +1 more source